| The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion |
|
Annals of Hematology |
Myelodysplastic Syndromes (MDS) |
| The role of androgen therapy in acquired aplastic anemia and other bone marrow failure syndromes |
|
Frontiers in Oncology |
Aplastic Anemia |
| The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents |
|
Current Hematologic Malignancy Reports |
Myelodysplastic Syndromes (MDS) |
| Therapy for lower-risk MDS |
|
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
| Therapy-related Myelodysplastic Syndromes Deserve Specific Diagnostic Sub-Classification and Risk-Stratification-An Approach to Classification of Patients With t-MDS |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
| Therapy-related myelodysplastic syndromes in the genomics era |
|
Bulletin du Cancer |
Myelodysplastic Syndromes (MDS) |
| Thrombosis at Unusual Sites: Focus on Myeloproliferative Neoplasms and Paroxysmal Nocturnal Hemoglobinuria |
|
Hamostaseologie |
Myeloproliferative Neoplasms (MPN), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Thrombosis at Unusual Sites: Focus on Myeloproliferative Neoplasms and Paroxysmal Nocturnal Hemoglobinuria |
|
Hamostaseologie |
Myeloproliferative Neoplasms (MPN), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Thrombosis in Paroxysmal Nocturnal Hemoglobinuria (PNH): From Pathogenesis to Treatment |
|
International Journal of Molecular Sciences |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
